Matinas BioPharma (MTNB) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts MTNB Hot Sheet
Join SI Premium – FREE
Matinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.03), in-line with the analyst estimate of ($0.03).
For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Texas Capital Securities Starts Red Rock Resorts (RRR) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
